Cytokinetics (CYTK) PT Raised to $110 at Citizens on Strong MYQORZO Launch
Tweet Send to a Friend
Citizens analyst Jason Butler raised the price target on Cytokinetics (NASDAQ: CYTK) to $110.00 (from $105.00) while maintaining a Market ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
